No, it was an independent process. It was peer-reviewed. None of the bids met the minimum standard. At the same time, the Gates Foundation had done a review of international capacity. In the intervening year and a half or two years, there was increasing capacity available in Canada and elsewhere.
So we didn't have any proposals that we could fund, because none of them met the standard. At the same time, we realized that there was new capacity out there that could be made use of. So why put money into bricks and mortar when you can further research that will speed up the development of a vaccine?
It became redundant. None were successful because none met the standard. So it became a redundant program—not a wise use of investment dollars.